Role of the metabolic syndrome in risk assessment for coronary heart disease

JAMA

Volumn 295, Issue 7, 2006, Pages 819-821

  Kohli, Priya ^a   Greenland, Philip ^b  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AREA UNDER THE CURVE; BLOOD PRESSURE; CONFIDENCE INTERVAL; CORONARY RISK; DIET THERAPY; EXERCISE; FALSE POSITIVE RESULT; FOLLOW UP; GENERAL PRACTICE; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; STROKE; UNIVARIATE ANALYSIS; WEIGHT REDUCTION;

EID: 32644451825     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.7.819     Document Type: Note

References (27)

1. Ahrens EH Jr. The management of hyperlipidemia: whether, rather than how. Ann Intern Med. 1976;85:87-93.
2. Unal B, Critchley JA, Capewell S. Modeling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. BMJ. 2005;331:614.
3. Hunink MG, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment. JAMA. 1997;277:535-542.
4. Hu FB, Stampfer MJ, Manson JE, et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med. 2000;343:530-537.
5. Grundy SM, Balady GJ, Criqui MH, et al; American Heart Association. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. Circulation. 1998;97:1876-1887.
6. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999;100:1481-1492.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
8. Robson J, Boomla K, Hart B, Feder G. Estimating cardiovascular risk for primary prevention: outstanding questions for primary care. BMJ. 2000;320:702-704.
9. Ginsburg GS, Donahue MP, Newby LK. Prospects for personalized cardiovascular medicine: the impact of genomics. J Am Coll Cardiol. 2005;46:1615-1627.
10. Pearson TA, Blair SN, Daniels SR, et al; American Heart Association Science Advisory and Coordinating Committee. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388-391.
11. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
12. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310-315.
13. Ferrario M, Chiodini P, Chambless LE, et al; CUORE Project Research Group. Prediction of coronary events in a low incidence population: assessing accuracy of the CUORE cohort study prediction equation. Int J Epidemiol. 2005;34:413-421.
14. Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis. 2005;181:93-100.
15. Stephens JW, Ambler G, Vallance P, Betteridge DJ, Humphries SE, Hurel SJ. Cardiovascular risk and diabetes: are the methods of risk prediction satisfactory? Eur J Cardiovasc Prev Rehabil. 2004;11:521-528.
16. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
17. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:2644-2650.
18. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
19. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
20. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27:2676-2681.
21. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities study. Diabetes Care. 2005;28:385-390.
22. Yarnell JW, Patterson CC, Bainton D, Sweetnam PM. Is metabolic syndrome a discrete entity in the general population? evidence from the Caerphilly and Speedwell population studies. Heart. 1998;79:248-252.
23. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention study. Circulation. 2003;108:414-419.
24. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245-1250.
25. Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-1214.
26. Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association. National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
27. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-2304.